Could Kineret® reduce inflammation in stroke patients?

Written by Sharon Salt

In a recently published study in Stroke, researchers have revealed that the anti-inflammatory drug, Kineret®, could reduce inflammation when given to patients in the early stages of a stroke. Kineret is currently licensed for treatment of rheumatoid arthritis and works by blocking the actions of IL-1, which is released into the body following injury caused by a stroke. The single-center, double-blind, randomized, placebo-controlled Phase II trial (SCIL-STROKE) was funded by the Stroke Association and follows earlier research that demonstrate the drug reduces inflammation in stroke and subarachnoid hemorrhage patients. 80 participants took part in the study and were assigned either...

To view this content, please register now for access

It's completely free